Trial Profile
Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Elbasvir/grazoprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Mar 2020 Status changed from active, no longer recruiting to completed.
- 21 May 2019 Planned End Date changed from 30 Dec 2019 to 20 Feb 2020.
- 21 May 2019 Planned primary completion date changed from 30 Sep 2019 to 25 Nov 2019.